A citation-based method for searching scientific literature

Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, Luca Rinaldi, Anna Di Martino, Gaetana Albanese, Jessica Di Salvo, Raffaella Epifani, Raffaele Marfella, Giovanni Docimo, Miriam Lettieri, Celestino Sardu, Ferdinando Carlo Sasso. Int J Mol Sci 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
947
100

Cardiac Tissue Injury and Remodeling Is Dependent Upon MR Regulation of Activation Pathways in Cardiac Tissue Macrophages.
Jimmy Z Shen, James Morgan, Greg H Tesch, Amanda J Rickard, Sophocles Chrissobolis, Grant R Drummond, Peter J Fuller, Morag J Young. Endocrinology 2016
39
100

Kidney outcomes with finerenone: An analysis from the FIGARO-DKD study.
Luis M Ruilope, Bertram Pitt, Stefan D Anker, Peter Rossing, Csaba P Kovesdy, Roberto Pecoits-Filho, Pablo Pergola, Amer Joseph, Andrea Lage, Nicole Mentenich,[...]. Nephrol Dial Transplant 2022
1
100

Chronic kidney disease and cardiovascular complications.
Luca Di Lullo, Andrew House, Antonio Gorini, Alberto Santoboni, Domenico Russo, Claudio Ronco. Heart Fail Rev 2015
128
100

Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
Shigeru Shibata, Miki Nagase, Shigetaka Yoshida, Hiroshi Kawachi, Toshiro Fujita. Hypertension 2007
274
100

Novel mineralocorticoid receptor mechanisms regulate cardiac tissue inflammation in male mice.
Gregory S Y Ong, Timothy J Cole, Gregory H Tesch, James Morgan, Jennifer K Dowling, Ashley Mansell, Peter J Fuller, Morag J Young. J Endocrinol 2020
4
100

Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats.
Akira Nishiyama, Li Yao, Yukiko Nagai, Kayoko Miyata, Masanori Yoshizumi, Shoji Kagami, Shuji Kondo, Hideyasu Kiyomoto, Takatomi Shokoji, Shoji Kimura,[...]. Hypertension 2004
247
100

Diagnosis and Management of Type 2 Diabetic Kidney Disease.
Simit M Doshi, Allon N Friedman. Clin J Am Soc Nephrol 2017
105
100

Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Gerasimos Filippatos, George L Bakris, Bertram Pitt, Rajiv Agarwal, Peter Rossing, Luis M Ruilope, Javed Butler, Carolyn S P Lam, Peter Kolkhof, Luke Roberts,[...]. J Am Coll Cardiol 2021
20
100

Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry.
Aldo P Maggioni, Stefan D Anker, Ulf Dahlström, Gerasimos Filippatos, Piotr Ponikowski, Faiez Zannad, Offer Amir, Ovidiu Chioncel, Marisa Crespo Leiro, Jaroslaw Drozdz,[...]. Eur J Heart Fail 2013
420
100

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
100

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
Gerasimos Filippatos, Bertram Pitt, Rajiv Agarwal, Dimitrios Farmakis, Luis M Ruilope, Peter Rossing, Johann Bauersachs, Robert J Mentz, Peter Kolkhof, Charlie Scott,[...]. Eur J Heart Fail 2022
3
100

Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1.
Jonatan Barrera-Chimal, Gwennan André-Grégoire, Aurelie Nguyen Dinh Cat, Sebastian M Lechner, Jérôme Cau, Sonia Prince, Peter Kolkhof, Gervaise Loirand, Vincent Sauzeau, Thierry Hauet,[...]. J Am Soc Nephrol 2017
45
100

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph,[...]. N Engl J Med 2020
381
100


Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice.
Benjamin Bonnard, Marie Pieronne-Deperrois, Zoubir Djerada, Soumaya Elmoghrabi, Peter Kolkhof, Antoine Ouvrard-Pascaud, Paul Mulder, Frédéric Jaisser, Smail Messaoudi. J Mol Cell Cardiol 2018
19
100

Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.
Michael G Usher, Sheng Zhong Duan, Christine Y Ivaschenko, Ryan A Frieler, Stefan Berger, Günther Schütz, Carey N Lumeng, Richard M Mortensen. J Clin Invest 2010
273
100

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Gerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, Luis M Ruilope, Peter Rossing, George L Bakris, Christoph Tasto, Amer Joseph, Peter Kolkhof, Andrea Lage,[...]. Circulation 2022
7
100

Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Peter Kolkhof, Martina Delbeck, Axel Kretschmer, Wolfram Steinke, Elke Hartmann, Lars Bärfacker, Frank Eitner, Barbara Albrecht-Küpper, Stefan Schäfer. J Cardiovasc Pharmacol 2014
170
100

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Bertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, Stefan D Anker, George L Bakris, Peter Rossing, Amer Joseph, Peter Kolkhof, Christina Nowack, Patrick Schloemer,[...]. N Engl J Med 2021
111
100

Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts.
Yukiko Nagai, Kayoko Miyata, Guang-Ping Sun, Matlubur Rahman, Shoji Kimura, Akira Miyatake, Hideyasu Kiyomoto, Masakazu Kohno, Youichi Abe, Masanori Yoshizumi,[...]. Hypertension 2005
124
100

Osteopontin in rat renal fibroblasts: functional properties and transcriptional regulation by aldosterone.
Jun Irita, Takafumi Okura, Mie Kurata, Ken-ichi Miyoshi, Tomikazu Fukuoka, Jitsuo Higaki. Hypertension 2008
35
100

Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats.
Y Sun, J Zhang, J Q Zhang, F J Ramires. Hypertension 2000
151
100

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress.
Lionel Lattenist, Sebastian M Lechner, Smail Messaoudi, Alan Le Mercier, Soumaya El Moghrabi, Sonia Prince, Norma A Bobadilla, Peter Kolkhof, Frédéric Jaisser, Jonatan Barrera-Chimal. Hypertension 2017
52
100

Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy.
Jana Grune, Verena Benz, Sarah Brix, Janek Salatzki, Annelie Blumrich, Beata Höft, Robert Klopfleisch, Anna Foryst-Ludwig, Peter Kolkhof, Ulrich Kintscher. J Cardiovasc Pharmacol 2016
42
100

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.
Bertram Pitt, Lars Kober, Piotr Ponikowski, Mihai Gheorghiade, Gerasimos Filippatos, Henry Krum, Christina Nowack, Peter Kolkhof, So-Young Kim, Faiez Zannad. Eur Heart J 2013
283
100

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice.
Marie Pieronne-Deperrois, Alexandre Guéret, Zoubir Djerada, Clément Crochemore, Najah Harouki, Jean-Paul Henry, Anaïs Dumesnil, Marine Larchevêque, Jean-Claude do Rego, Jean-Luc do Rego,[...]. ESC Heart Fail 2021
6
100

Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study.
Takashi Wada, Masaya Inagaki, Toru Yoshinari, Ryuji Terata, Naoko Totsuka, Miki Gotou, Gaia Hashimoto. Clin Exp Nephrol 2021
20
100

Spironolactone for heart failure with preserved ejection fraction.
Bertram Pitt, Marc A Pfeffer, Susan F Assmann, Robin Boineau, Inder S Anand, Brian Claggett, Nadine Clausell, Akshay S Desai, Rafael Diaz, Jerome L Fleg,[...]. N Engl J Med 2014
100

Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
Cristián A Amador, Víctor Barrientos, Juan Peña, Andrés A Herrada, Magdalena González, Solange Valdés, Loreto Carrasco, Rodrigo Alzamora, Fernando Figueroa, Alexis M Kalergis,[...]. Hypertension 2014
135
100

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Juliana C N Chan, Adriaan Kooy, Kieran McCafferty, Guntram Schernthaner,[...]. Kidney Int Rep 2021
17
100

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.
Ralph A DeFronzo, W Brian Reeves, Alaa S Awad. Nat Rev Nephrol 2021
68
100

NLRP3 Inflammasome and Mineralocorticoid Receptors Are Associated with Vascular Dysfunction in Type 2 Diabetes Mellitus.
Nathanne Santos Ferreira, Thiago Bruder-Nascimento, Camila André Pereira, Camila Zillioto Zanotto, Douglas Silva Prado, Josiane Fernandes Silva, Diane Meyre Rassi, Maria Cristina Foss-Freitas, Jose Carlos Alves-Filho, Daniela Carlos,[...]. Cells 2019
32
100

Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the Risks.
Murray Epstein, Roberto Pecoits-Filho, Catherine M Clase, Manish M Sood, Csaba P Kovesdy. Clin J Am Soc Nephrol 2022
2
100

Mineralocorticoid Receptor Deficiency in Macrophages Inhibits Neointimal Hyperplasia and Suppresses Macrophage Inflammation Through SGK1-AP1/NF-κB Pathways.
Jian-Yong Sun, Chao Li, Zhu-Xia Shen, Wu-Chang Zhang, Tang-Jun Ai, Lin-Juan Du, Yu-Yao Zhang, Gao-Feng Yao, Yan Liu, Shuyang Sun,[...]. Arterioscler Thromb Vasc Biol 2016
45
100

Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics.
Jonatan Barrera-Chimal, Peter Kolkhof, Ixchel Lima-Posada, Alexandre Joachim, Patrick Rossignol, Frederic Jaisser. Expert Opin Investig Drugs 2021
4
100

A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases.
Kitty J Jager, Csaba Kovesdy, Robyn Langham, Mark Rosenberg, Vivekanand Jha, Carmine Zoccali. Kidney Int 2019
92
100

Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
N J Brown, S Nakamura, L Ma, I Nakamura, E Donnert, M Freeman, D E Vaughan, A B Fogo. Kidney Int 2000
217
100

Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
Michele Provenzano, Maria Jesús Puchades, Carlo Garofalo, Niels Jongs, Luis D'Marco, Michele Andreucci, Luca De Nicola, Jose Luis Gorriz, Hiddo J L Heerspink. J Am Soc Nephrol 2022
1
100

The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling.
Daniel Lavall, Nadine Jacobs, Felix Mahfoud, Peter Kolkhof, Michael Böhm, Ulrich Laufs. Biochem Pharmacol 2019
19
100

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, Rajiv Agarwal, Clare Arnott, George Bakris, Christopher P Cannon, David M Charytan, Robert Edwards, Jose L Górriz,[...]. Eur Heart J 2021
28
100

Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
Jonatan Barrera-Chimal, Ixchel Lima-Posada, George L Bakris, Frederic Jaisser. Nat Rev Nephrol 2022
10
100

Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
Matthew R Weir, David A Bushinsky, Wade W Benton, Steven D Woods, Martha R Mayo, Susan P Arthur, Bertram Pitt, George L Bakris. Am J Med 2018
29
100

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
100

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Gerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Patrick Schloemer, Ingo Tornus, Amer Joseph,[...]. Circulation 2021
80
100

Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
Karoline Droebner, Mira Pavkovic, Manuel Grundmann, Elke Hartmann, Laura Goea, Johannes Nordlohne, Jürgen Klar, Frank Eitner, Peter Kolkhof. Am J Nephrol 2021
8
100


Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats.
Beatriz Martín-Fernández, Alfonso Rubio-Navarro, Isabel Cortegano, Sandra Ballesteros, Mario Alía, Pablo Cannata-Ortiz, Elena Olivares-Álvaro, Jesús Egido, Belén de Andrés, María Luisa Gaspar,[...]. PLoS One 2016
55
100

Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms.
Dong Chen, Zhiyong Chen, Chanyoung Park, Michael Centrella, Thomas McCarthy, Li Chen, Ahmed Al-Omari, Gilbert W Moeckel. Gene 2013
27
100

Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
Rajiv Agarwal, Amer Joseph, Stefan D Anker, Gerasimos Filippatos, Peter Rossing, Luis M Ruilope, Bertram Pitt, Peter Kolkhof, Charlie Scott, Robert Lawatscheck,[...]. J Am Soc Nephrol 2022
13
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.